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Background: Difficult to control asthma accounts for significant morbidity and healthcare cost,
and non-adherence to medication is a common cause. It remains unclear if targeting non-
adherence in this population improves healthcare outcomes.
Methods: All subjects were referred to a Specialist Difficult Asthma Service (60% from Respira-
tory physicians); poor adherence was identified using prescription refill records for inhaled
combination therapy. A sequential 2 phase study examined the effect of identifying and tar-
geting non-adherence to inhaled long-acting b-agonist/inhaled steroid combination therapy;
phase 1 e an observational study utilising objective measures of non-adherence to facilitate
a medical concordance discussion followed by phase 2, a 12 month prospective single blind
randomised controlled trial where subjects with persistent poor adherence were randomised
to a nurse-led menu driven intervention.
Results: A total of 239 patients were assessed; 31 of 83 subjects (37%) who were initially non-
adherent, significantly improved adherence after concordance interview, with reduced
prescribed daily dose of ICS (data p< 0.001), rescue prednisolone courses (data, p< 0.001)
and hospital admissions (data, pZ 0.006). With the menu driven intervention, adherence also
improved (intervention 37.6% to 61.9%, control group 31.7% to 28.8%) with reduced mainte-
nance oral steroid dose in subjects on maintenance steroids.
Conclusion: Poor adherence in difficult-to control asthma is common, but when identified and tar-
geted can be improved and this is associated with large improvements in important healthcare
outcomes. Previous nihilism towards non-adherence in this population is not supported by this study.
ª 2011 Elsevier Ltd. All rights reserved.l Respiratory Centre, Belfast City Hospital, Lisburn Road, Belfast BT9 7AB, Northern Ireland, UK.
0 263879.
uk (L.G. Heaney).
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Improving medication adherence in difficult asthma 1309Introduction through our multi-disciplinary assessment protocol, back to
15Asthma is a leading, preventable cause of morbidity,
mortality and economic burden, estimated to affect 300
million people worldwide.1,2 Despite treatment with high
dose therapy approximately 5% of adult patients remain
difficult to control with persisting symptoms and frequent
exacerbations.3 This sub-group of patients accounts for
a disproportionate amount of asthma morbidity and health
care costs and are a particular cause for concern because of
the potential consequences of uncontrolled disease
including fatal or near fatal asthma.4,5
We have previously reported a high prevalence of non-
adherence to inhaled and oral steroid medication, in adult
subjects referred to a Regional Difficult Asthma Service
(difficult asthma was defined as persistent symptoms despite
prescribed treatment at Step 4/5 of the British Thoracic
Society/Scottish Intercollegiate Guideline Network (BTS/
SIGN) treatment steps).6 We also demonstrated that non-
adherencewas associatedwith increasedhospital admissions,
impaired quality of life and was more common in women.6
A key question remains whether poor adherence can be
addressed in this difficult to control population. There is
data on adherence interventions in mild/moderate asthma,
where a recent Cochrane concluded that the evidence for
any intervention improving adherence was ‘surprisingly
weak’, with little suggestion that medication adherence
can be improved consistently and on a long term basis. This
review also concluded that increasing effectiveness of
adherence interventions might have a greater impact on
the health of the population than any improvement in
specific medical treatments.7
However, there is no data on interventions in adult
subjects with difficult asthma. We have previously reported
that patients with difficult asthma have individually specific
reasons for non-adherence, many of which (e.g. lack of
knowledge, drug misconceptions and steroid phobia) could
be addressed using an individualised menu driven inter-
vention.8 Techniques such as audio-visual reminders,
education and diary keeping and psychological or behav-
ioural based interventions, which have been positively
utilised used in mental health,9e14 also seemed to be
appropriate to utilise in subjects with difficult asthma.
The aim of this study was to determine if non-adherence
to inhaled combination LABA/steroid medication when
identified in difficult asthma, could be improved using (a)
a simple concordance interview and (b) a menu driven
psycho-educational intervention strategy, with better
asthma outcome.MethodsParticipants
All subjects were attending the Northern Ireland Regional
Difficult Asthma Service, which assesses 70e80 new
patients a year, of which 60% are tertiary referrals from
other Respiratory Specialists; at the time of the study, 239
patients were attending the Service. The Service has a ca
65% ‘discharge rate’ after assessment and stabilisationprimary care or to the referring Respiratory Specialist.
None of the subjects had non-adherence suspected as
a major clinical issue at the time of referral and all denied
non-adherence at the time of first clinical assessment at
the clinic. Difficult asthma was defined as persistent
symptoms, despite treatment at BTS/SIGN step 4/5.16Measuring adherence
Adherence was measured as previously described and
validated, using prescription refill records.6 In Northern
Ireland, all prescribed medication is obtained via
prescription from a single General Practitioner (GP) and
prescription refills for inhaled combination therapy (ICT)
were obtained for the previous 6 months and expressed as
a percentage of prescribed medication. Non-adherence was
defined as prescription filling of 50%, which again we have
validated as a meaningful ‘cut-off’ value for identifying
excessive healthcare utilisation and poor asthma outcome.6
Patient demographics, hospital admissions, lung func-
tion, oral prednisolone courses, and quality of life data
were obtained from medical records.
The study consisted of 2 phases and ethical approval for
the study was obtained from the Office for Research Ethics
Committees Northern Ireland (ORECNI). In Phase 1, when
non-adherence was identified, a patient concordance
discussion was arranged, which communicated the fact that
patients were non-adherent with medication and a treat-
ment plan was agreed to address poor adherence. The aim
of phase 1 was to examine the effect of both the commu-
nication to the patient, that the treating healthcare team
was aware of their non-adherence and the effect of the
concordance discussion. Patients who became adherent
after initial concordance discussion during this phase
(defined as adherent at Screen 2 e see below), were fol-
lowed up 6 months after this point to monitor their
adherence and asthma outcome.
All patients had prescription records rescreened after
the initial concordance discussion (Screen 2, time of screen
median 9 months [range 6e12]) to identify if their adher-
ence had altered and to determine if they were suitable for
the menu driven intervention phase of the study (Phase 2).
Subjects who remained non-adherent were approached to
enter phase 2. Inclusion criteria were 18 years of age,
attending the Difficult Asthma Service, a Juniper Asthma
Control Score 317 and remained non-adherent despite
participating in Phase 1. Exclusion criteria were current
tobacco smoking or significant other co-morbidity which
contributed to persisting respiratory symptoms.
The Phase 2 study was a 12 month prospective single
blind randomised controlled trial of an individualised
psycho-educational nurse-led intervention to improve
adherence to medication. Patients were randomly allo-
cated to either the intervention or control group. All
participants received standard asthma care at the difficult
asthma service but the control group did not receive any
further intervention. The intervention group subjects were
offered up to 8 individual intervention visits within a 12
week period. Subsequent follow-up visits for control and
Intervention group were conducted at 6 months and
1310 J. Gamble et al.12 months post-recruitment. Fig. 1 demonstrates patient
flow through the study.
The menu driven intervention was designed and deliv-
ered by an experienced respiratory nurse with basic level
psycho-therapy training. Although the proposed interven-
tion was unique in its design, to increase the internal val-
idity of the study, the Compliance Therapy Model was used
to provide the underpinning theoretical framework.18 This
model encompassed the Transtheoretical Model of Change,
Motivational Interviewing and Cognitive Behavioural
Therapy principles, providing a flexible short termFigure 1 Patient flowintervention using patient’s individual reasons for non-
adherence as a guide to plan intervention content. The
model used a non-confrontational technique which elicited
self-motivation and provided a process to resolve ambiva-
lence towards medication taking.
Outcome variables
The primary outcome for both study phases was change in
adherence to ICT. Two indicators of change in adherence
were measured; change in % of ICT prescriptions refilledthrough the study.
Improving medication adherence in difficult asthma 1311and change in number of participant’s filling 50% of
prescription refills for ICT in each group. Secondary
outcomes included daily prescribed dose of inhaled corti-
costeroid (ICS), courses of rescue oral corticosteroids, total
inhaled and nebulised beta-agonist doses, hospital admis-
sions and lung function (spirometry) as well as Asthma
Control Questionnaire (ACQ),17 Asthma Quality of Life Score
(AQLQ)19 and Hospital Anxiety and Depression Scale/State
Trait Anxiety Scale (HADS).20
Data analysis
Data were coded and analysed using a Statistical Package
for Social Sciences (SPSS), Version 16.21 Descriptive statis-
tics are shown as mean SD, or median [range] for nor-
mally and non-normally distributed data as appropriate.
Between group testing was performed using t tests or Mann
Whitney test for continuous variables and Chi squared for
dichotomous variables (in cases where the expected
frequency fell below 5 the Fisher’s exact test was used).
For Phase 1 outcomes, a one-way person fixed, time
factor ANOVA was used to determine differences across
Baseline (Screen 1), Screen 2 and Screen 3. When normality
assumptions for ANOVA were not met, a non-parametric
Friedman Test was used.
For Phase 2 outcomes, a one-way analysis of co-variance
(ANCOVA), controlling for pre-test scores was used to
compare the differences between the groups. When
assumptions were not met, a non-parametric Man-
neWhitney U test for independent samples was used. A pre-
planned analysis using student t paired t-test (primary
outcome) and a one-way person fixed, time factor analysis
of variance (ANOVA) (secondary outcomes) to examine
intra-group changes was used as the ANCOVA testing
demonstrated an intervention effect. When assumptions
were not met a non-parametric Friedman Test was used.
Data are presented as mean SD or median, range.
Significance was taken as p< 0.05.Table 1 Adherence and clinical outcomes in the 31 subjects w
Adherence
Screen 1
Adherence Scree
[median 9 month
range 6e12 post
initial screen]
% Adherence to ICT 37.3 14.0 88.5 15.7
ICS daily dose (mg)b 1616.1 490.0 1293.6 560.5
No. courses rescue
prednisolone
2.2 1.5 0.6 1.1
Maintenance prednisolone
dose(mg), (nZ 34)
14.1 6.1 13.1 5.9
Total b2-agonist doses 1705.2 2523.9 1481.9 2072.9
Total b2-agonist nebules 221.5 327.9 93.3 140.1
FEV1 (l) 2.1  0.7 2.2 0.7
FEV1 % 74.4  20.5 77.0 21.4
FEV1 /FVC 68.3 13.1 67.2 15.1
Data are presented as mean SD.
a Significance was taken at p< 0.05.
b Bioequivalence of inhaled steroids was fluticasoneZ 2 beclomeResults
Phase 1
During Phase 1, 31 of 83 (37%) subjects became adherent
after concordance discussion. They were predominantly
female (nZ 21 [68%], age 45 14.6 y); 12 (39%) had been
referred from another Respiratory physician with apparent
severe refractory asthma.
Outcome data for adherence screen 2 (median 9 months,
range 6e12 after concordance discussion) and adherence
screen 3 (6 months after screen 2), for these 31 subjects are
shown in Table 1. At screen 3, 27 of the 31 subjects (90%)
remained adherent (still filling >50% prescription for ICT)
and overall % adherence was also significantly better for the
group.
The prescribed daily dose of ICS (p< 0.001) and the
number of rescue courses of oral prednisolone required
(p< 0.001) were significantly improved and there was
a significant decrease in the number of patients requiring at
least one course of rescue prednisolone (p< 0.001). In
total, 16 (52%) patients did not require any rescue courses
of prednisolone for at least 12 months post discussion.
Improvements were seen in FEV1 (pZ 0.01) and FEV1%
predicted (pZ 0.05) and there was a statistically signifi-
cant reduction in the number of admissions to hospital with
an exacerbation of asthma across the 3 time periods
(pZ 0.006) (Fig. 2).
Of the remaining 83 subjects identified as non-adherent
at Screen 1, 10 failed to re-attend the service after non-
adherence was identified and discussed. At Screen 2, 8
subjects had low symptom scores despite poor medication
adherence (asthma control score< 3), 13 subjects met
exclusion criteria (6 current smokers, 4 significant co-
morbidity precluding definite improvement with medication
adherence, severe allergic bronchopulmonary aspergillosis,
severe personality disorder, prominent co-existent
dysfunctional breathlessness and severe bronchiectasis)ho became adherent after initial concordance discussion.
n 2
s,
Adherence
Screen 3
[6 months
after Screen 2]
F p Value CI
82.3 24.3 59.58 <0.001 16.9 to 28.7
1280.7 557.6 17.61 <0.001a 247.7 to 87.8
0.7 1.0 33.76 <0.001a 1.0 to 0.5
11.5 4.7 1.66 0.22 2.2 to 0.5
1500.0 2658.8 1.16 0.29 267.7 to 80.6
169.3 218.4 1.05 0.32 102.3 to 34.2
2.2 0.6 6.50 0.01a 0.0 to 0.2
75.5 17.2 4.09 0.05a 0.0 to 6.8
63.2 12.4 0.71 0.40 2.6 to 1.1
thasoneZ 2 budesonide.
Figure 2 Hospital admissions for the preceding 6 month
periods at adherence screen 1 (pre-concordance discussion),
and at adherence screen 2 (median 9 months, range 6e12) and
adherence screen 3 (6 months post screen 2) in the 31 subjects
who became adherent after initial concordance discussion.
1312 J. Gamble et al.and 3 subjects were excluded due to age less than
18 years.
Phase 2
Of the initial 239 patients at Screen 1, 207 were excluded
(Fig. 1), and nZ 12 refused to take part in the study,
resulting in 20 eligible subjects; 9 were randomised to the
intervention group and 11 in the control group. Demo-
graphic details are shown in Table 2.
Two participants randomised to the intervention group,
after initial consent to participation, did not attend for
the intervention visits and were not included in the follow
up. All other participants remained in the study for the
full duration.Table 2 Baseline characteristics of the Phase 2 study participa
Demographics Groups
Interven
Female (%) 7 (78%
Age (SD) 50.0 (9.1
Duration of asthma (years) (median, range) 38 (9e
Marital status (%)
Married 5 (56%
Single 1 (11%
Other 3 (33%
Employment status (%)
Working 3 (33%
Retired/pension 1 (11%
Disability/benefits 5 (56%
Source of referral (%)
Tertiary 5 (56%
GP 4 (44%
Smoking history
Ex (%) 2 (22%
Pack year history (Median, range) 27.5 (1eEffects of the intervention at 12 months
The primary outcome (%ICT inhalers filled) was significantly
improved (intervention increased from 37.6% to 61.9%,
control group 31.7% to 28.8%, pZ 0.01, Fig. 3). There was
also an increase in the number of participants in the
intervention group filling >50% of prescription refills for ICT
(intervention group, 4 of 7 filling >50% v 1 of 10 filling >50%
in the control groupZ 0.05). Based on these changes, the
number needed to treat (NNT) was calculated as follows;
90.9% of the control group had no change in adherence at
12 months, compared to 42.9% of the intervention group.
The difference, the absolute risk ratio (AAR) was 48.5% (95%
CI 7.65% to 88.46%) estimating the NNT to be 3 (95% CI 1.1
to 13.1).
There was a significant difference in daily prescribed
dose of maintenance prednisolone in subjects on oral
steroids (intervention group, 4 subjects, mean 9.4 mgs v
control group, 3 subjects 20.0 mgs, pZ 0.001). There were
no other between group differences identified (Table 3).
There was a trend towards a decrease in the number of
rescue courses of oral prednisolone required in the inter-
vention group, though this did not reach statistical signifi-
cance (mean 3.2 mgs to 1.7 mgs, pZ 0.09).
Discussion
We have previously reported a high level of poor adherence
with ICT in subjects referred to our Regional Difficult
Asthma Service, many of whom had been referred from
other respiratory specialists with apparent ‘severe refrac-
tory asthma’ where adherence to medication was not
objectively assessed or addressed.6 This study examined
whether identification and addressing poor ICT adherence
using an objective measure in this population can alter
clinical outcome. All patients in this study had receivednts.
tion (nZ 9) Control (nZ 11) p Value
) 10 (91%) 0.57
) 45.2 (10.0) 0.28
52) 30 (14e50) 0.55
) 8 (73%) 0.71
) 1 (9%)
) 2 (18%)
) 4 (36%) 0.53
) 0 (0%)
) 7 (64%)
) 5 (45%) 1.00
) 6 (55%)
) 3 (27%) 1.00
35) 20 (1e20) 0.26
Figure 3 Adherence to ICT (% prescription filling) between
baseline, 6 and 12 months for 20 subjects randomised to
control and intervention arms during Phase 2 of study. *Error
bars represent SE of percent adherence.
Improving medication adherence in difficult asthma 1313asthma education as part of their initial difficult asthma
assessment and had denied poor adherence as part of this
assessment.
In phase 1 of this study, patients identified as poorly
adherent with ICT had a physician led feedback discussion
regarding their prescription refills. After this concordance
discussion, 31 of 83 subjects became adherent with signif-
icantly better asthma outcome. Our feedback discussion
findings are supported by the outcomes of an RCT using
a similar intervention in subjects with mild to moderate
asthma.22 Regular direct clinician-to-patient feedback andTable 3 Between group differences for baseline, 6 and 12 month
during Phase 2 of study.
Outcomes Baseline 6 mont
Intervention,
nZ 9
Control,
nZ 11
Interve
nZ 7
Number (%) filling 50%
of ICT prescriptions
0 of 9 (0%) 0 of 11(0%) 3 of 7
ICS daily dose (mg)b 1467 529.2 1346  651.7 1314
b2-agonist doses filled 4022 7194.8 2200 1817.7 4400
Total b2-agonist nebules
filled
75 87.0 136 131.6 105
Daily maintenance
prednisolone dose (mg)
15.0 16.8
(nZ 4)
16.7 7.6
(nZ 3)
9.38
Hospital Admissions
(median/range)
0 (0e1) 0 (0e1) 0 (0e1
FEV1 % predicted 77.1 24.8 78.7 21.8 79.3
Rescue courses oral
prednisolone
3.2 1.9 2.6 1.5 1.1
AQLQ total domain scores 3.4 1.0 3.4 1.1 3.9
Asthma control score 3.7 0.7 4.0 0.9 2.9
Anxiety (HADS) 9.7 3.8 10.6 3.4 10.6
Depression (HADS) 6.8 1.9 7.6 4.1 6.4
Data are presented as mean SD unless otherwise stated.
a Significance was taken at p< 0.05.
b Bioequivalence of inhaled steroids was fluticasoneZ 2 beclomediscussion of inhaled steroid use was shown to improve
adherence, with the intervention group having sustained
levels of adherence >70% compared with those in the
control group whose adherence rate fell below 30%. In this
study, the follow up period was only 10 weeks, and in
contrast to our study, there were no significant between
group differences in any of the reported asthma outcomes.
Several other studies in chronic health conditions have also
demonstrated improvement in adherence using patient
feedback mechanisms, but improved asthma outcome data
has not been consistently seen.23e25 Our study demon-
strates that in adult subjects with difficult to control
asthma when poor adherence is identified and a concor-
dance discussion takes place, adherence is improved in
a substantial proportion of subjects including those
referred from specialist physicians. In addition, we have
demonstrated that this improved adherence is associated
with a significant improvement in healthcare outcome in
this more difficult to manage population.
We were surprised at the size of the effect of a relatively
simple concordance discussion in this patient group. It is
not possible to be precise about what causes the alteration
in behaviour and specifically whether it is the concordance
discussion per se, or the fact that patients know they are
being monitored more closely. Developing a system to
feedback adherence information routinely to both clini-
cians and patients may result in improved adherence and
better asthma control.26 However, we believe that the key
issue is the identification of the non-adherence, which
requires a systematic approach using objective measures,
as all of these subjects initially denied non-adherence and
only admitted this was a problem when objective data was
presented to them.s for 20 subjects randomised to control and intervention arms
hs 12 months P
valuention, Control,
nZ 11
Intervention,
nZ 7
Control,
4nZ 11
(43%) 3 of 11(27%) 4 of 7 (57%) 1 of 11 (9%) 0.05a
641.4 1418 807.2 1314 641.4 1491 781.6 0.14
6420.8 2300 1273.6 4714 6970.3 1900 1313.8 0.91
75.5 128 144.9 90 88.7 152 171.8 0.99
7.2 20.0 5.0 9.38 7.2 20.0 5.0 0.001a
) 0 (0e2) 0 (0e1) 0 (0e3) 0.28
29.6 69.0 27.0 72.4 24.7 67.2 26.7 0.22
1.4 2.45 1.8 1.7 1.1 2.0 1.4 0.41
1.2 3.4 1.4 4.3 1.4 3.8 1.6 0.75
1.1 3.5 1.2 2.9 1.4 3.1 1.6 0.74
5.3 10.9 4.2 8.9 3.6 9.8 3.9 0.46
2.9 8.1 3.7 5.4 3.4 7.4 4.6 0.38
thasoneZ 2 budesonide.
1314 J. Gamble et al.We anticipated that a number of patients would remain
persistently non-adherent and we wished to identify if we
could deliver amore individualised approach to address their
non-adherence. We also noted that some patients who were
initially adherent by prescription records, when rescreened
were non-adherent (nZ 11, initial adherence measure was
72.8% 11.1%). This suggests adherence is a dynamic vari-
able which varies with time in individual subjects.
The number of study entry refusals and subsequent
failures to attend also illustrates the problems performing
clinical trials on adherence in this population of patients.
Thus, whilst the number of subjects randomised to the
intervention appears small, we believe that a larger study is
not feasible in a single centre setting, and a larger study
will require a multi-centre approach. However, despite the
small numbers, our menu driven intervention study still met
its primary outcome with increased adherence to ICT at 12
months in the intervention group. A similar education based
intervention in mild asthma also found some differences in
outcomes at 6 months, but at 12 months additional signif-
icant improvements were seen in AQLQ, peak expiratory
flow rate and willingness to adjust medication, highlighting
the fact that changes in patient behaviour can evolve with
time.27 Importantly, in our study the NNT was 3 (95% CI 1.1
to 13.1) suggesting that in adults with difficult asthma and
persistently poor adherence, a similar individualised
intervention may deliver substantially improved healthcare
outcomes when used in small numbers of patients.
We also demonstrated a reduction in prescribed main-
tenance oral steroid dose after our menu driven interven-
tion, but it is difficult to know how relevant this is, as we
have previously shown an association with poor compliance
to oral steroids and ICT.6 Consistent with this, 3 of the 7
subjects in Phase 2 of the study, who were prescribed
‘maintenance steroids’ were non-adherent using plasma
prednisolone/cortisol measurements. The failure to
demonstrate improved healthcare outcomes in Phase 2 of
the study probably reflects the small number of patients
taking part, however based on the Phase 1 data and our
understanding of the effects of improved adherence; it
seems probable that over a longer period of time or with
greater numbers of patients, such benefits would be seen.
This statement is supported by the fact that we did see
a non-significant trend towards reduced admissions in the
intervention group at 12 months (pZ 0.08).
Results from Phase 2 of this study compare favourably
with those from previous intervention studies for poor
medication adherence. In chronic health conditions, some
interventions have been successful in altering medication
adherence, with 26 of 58 interventions in a Cochrane
review associated with improvements in adherence.7
However importantly, in these studies, despite improved
adherence, only 18 showed any improvement in 1 or more
healthcare outcomes.7 A study using a psycho-educational
intervention to improve medication in adults with mild
asthma also demonstrated improvements in adherence; but
results were limited by the use of self-reported adherence
and a relatively short follow up period.28 Thus, the effect
size seen in our intervention study, albeit in small numbers
of patients for the reasons outlined above, compares
favourably with other studies in patients with different
conditions requiring chronic use of medication.Conclusion
In summary, this study confirms that poor adherence is
identified badly by physician assessment and patient self
report, and highlights the importance of using objective
measures of adherence as part of a difficult asthma
assessment. It also demonstrates that when this informa-
tion is presented to patients in a concordance discussion,
there is a significant alteration in patient behaviour with
improved adherence and asthma outcome. In addition,
a relatively simple menu driven intervention strategy,
which could be easily incorporated into a clinical manage-
ment programme, can further improve adherence in this
patient group.Conflict of interest statement
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